RedHill Biopharma Provides Update on BEKINDA(TM) Ongoing Phase III Study for Gastroenteritis and Announces Planned Phase II Study ...
Based on recent U.S. FDA feedback and prior feedback from the UK MHRA, RedHill believes that the ongoing Phase III study with BEKINDA™ for gastroenteritis (the GUARD study) may be sufficient as a single study to support the filing of a marketing …